Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biocryst Pharmaceuticals Inc (BCRX)  
$6.31 0.13 (2.02%) as of 4:30 Fri 6/7


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 189,490,000
Market Cap: 1.20(B)
Last Volume: 3,291,159 Avg Vol: 4,448,162
52 Week Range: $4.13 - $8.81
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 16.9
Insider 6 Months    : 16.9
Insider 3/6 Months : 32.4
Guru Rank Number :  455
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 183,601 183,601 183,601 183,601
Total Buy Value $1,048,338 $1,048,338 $1,048,338 $1,048,338
Total People Bought 10 10 10 10
Total Buy Transactions 10 10 10 10
Total Shares Sold 0 0 16,866 495,199
Total Sell Value $0 $0 $135,363 $5,999,241
Total People Sold 0 0 2 9
Total Sell Transactions 0 0 2 14
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 475
  Page 14 of 19  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-20 4 OE $3.78 $12,285 D/D 3,250 144,710     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-16 4 D $8.80 $108,310 D/D (12,308) 141,460     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-16 4 OE $1.42 $108,300 D/D 36,455 153,768     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-10 4 AS $9.06 $29,445 D/D (3,250) 117,313     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-10 4 OE $3.78 $12,285 D/D 3,250 120,563     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-08 4 AS $8.20 $54,763 D/D (6,500) 117,313     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-08 4 OE $3.78 $24,570 D/D 6,500 123,813     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-06 4 AS $7.90 $25,675 D/D (3,250) 117,313     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-03-06 4 OE $3.78 $12,285 D/D 3,250 120,563     -
   Ingram Robert Alexander Director   •       •      –    2017-03-02 4 A $6.24 $9,996 D/D 1,602 5,823     -
   Hutson Nancy J Director   •       •      –    2017-03-01 4 A $6.24 $9,996 D/D 1,602 30,266     -
   Cohen Fred E Director   •       •      –    2017-03-01 4 A $6.24 $9,996 D/D 1,602 117,469     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2017-01-20 4 D $5.95 $30,244 D/D (5,083) 104,706     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2017-01-20 4 D $5.95 $15,464 D/D (2,599) 75,497     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-01-20 4 D $5.95 $30,928 D/D (5,198) 117,313     -
   Sheridan William P Senior VP - CMO   •       •      –    2017-01-20 4 D $5.95 $34,278 D/D (5,761) 82,916     -
   Stonehouse Jon P President & CEO   •       •      –    2017-01-20 4 D $5.95 $62,903 D/D (10,572) 645,418     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2017-01-01 4 D $6.33 $10,375 D/D (1,639) 109,789     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2017-01-01 4 D $6.33 $8,109 D/D (1,281) 78,096     -
   Sheridan William P Senior VP - CMO   •       •      –    2017-01-01 4 D $6.33 $13,173 D/D (2,081) 88,677     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2017-01-01 4 D $6.33 $10,609 D/D (1,676) 122,511     -
   Stonehouse Jon P President & CEO   •       •      –    2017-01-01 4 D $6.33 $54,406 D/D (8,595) 655,990     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2016-12-19 4 AS $7.45 $24,213 D/D (3,250) 124,187     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2016-12-19 4 OE $3.78 $12,285 D/D 3,250 127,437     -
   Ingram Robert Alexander Director   •       •      –    2016-12-01 4 A $5.59 $9,995 D/D 1,788 4,221     -
  475 Records found
  Previous  10  11  12  13  14  15  16  17  18  19   
  Page 14 of 19
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us